Company news

Indivior Pharmaceuticals, Inc. news in 2025

Indivior Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Indivior Announces Inclusion in the S&P SmallCap 600® Index

December 21, 2025

New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations

December 17, 2025

Indivior Concludes Legacy U.S. Department of Justice Matter

November 20, 2025

Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 19, 2025

Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

November 3, 2025

Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

October 29, 2025

Indivior to Participate in the Stifel 2025 Healthcare Conference

October 28, 2025

Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

October 16, 2025

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

October 14, 2025

Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

October 1, 2025

Indivior to Participate in Upcoming Investor Events

August 20, 2025

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

July 30, 2025

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

July 24, 2025

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

July 23, 2025

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

July 17, 2025

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

July 7, 2025

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

June 29, 2025

Indivior Appoints Tony Kingsley to the Board of Directors

June 23, 2025

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

June 19, 2025

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

June 1, 2025

Indivior Announces Patrick Barry as Chief Commercial Officer

May 26, 2025

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

May 1, 2025

Indivior Announces Q1 2025 Financial Results

April 23, 2025

Indivior Announces Further Changes to Board of Directors

March 3, 2025

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

February 26, 2025

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

February 23, 2025

Indivior Announces FY and Q4 2024 Financial Results

February 19, 2025

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

February 11, 2025

Calls in 2025

Decks in 2025